April 21, 2017

Teva Pharmaceutical Industries Limited (NYSE:TEVA) simultaneous launch of AirDuo™ RespiClick® for treatment of asthma

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced the simultaneous launch of AirDuo™ RespiClick® (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for the treatment of asthma in patients aged 12 years and older who are uncontrolled on an inhaled corticosteroid (ICS) or whose disease severity clearly warrants the use of an ICS/long-acting beta2-adrenergic agonist (LABA) combination.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares ticked up 0.20% to $30.76 on Thursday.

AirDuo™ RespiClick® and its authorized generic are fixed-dose combination asthma therapies containing an ICS and a LABA, the same active ingredients as Advair®.
Technical Stock Analysis

Shares outstanding are recorded as 1011.79 billion and total shares floated are 913.43 million. Current ratio which is the relationship between current assets and current liabilities, indicating the liquidity of a business is calculated as 0.90. Company’s distance from 20 day simple moving average is -4.68% and distance from 50-Day simple moving average is -7.70%.

Best time to invest in stock market is when things are on odd side, and it’s not easy how to pick stocks. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision. Stock has got OUTPERFORM rating from 7 analysts of Thomson Reuters, 14 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for TEVA is $40.04 while analysts mean recommendation is 2.40.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) yearly performance is -43.86% and net profit margin is 0.30%. Annual EPS Growth of past 5 years is -53.00%. The current share price indicates that stock is -45.41% away from its one year high and is moving 0.39% ahead of its 52-week low.

Celanese Corporation (NYSE:CE) announced that its board of directors has approved a 28 percent increase in the company’s quarterly common stock cash dividend. The dividend rate increased from $0.36 to $0.46 per share of common stock on a quarterly basis and from $1.44 to $1.84 per share of common stock on an annual basis. The new dividend rate will be applicable immediately.
On 20 April 2017, Celanese Corporation (NYSE:CE) shares moved to $89.50 after starting the day at $88.20. Stock has got OUTPERFORM rating from 9 analysts of Thomson Reuters, 5 analysts given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for CE is $94.78 while analysts mean recommendation is 2.20.

At the movement New Gold Inc. (NYSE:NGD) is under coverage by number of analysts. Buy rating has been given by 1 analysts to the company stock whereas no analyst given UNDERPERFORM rating to stock and 11 analysts given HOLD rating. The consensus recommendation by Thomson Reuters analysts is Hold and their mean rating for the stock is 2.76 on scale of 1-5. Analysts mean target price for New Gold Inc. (NYSE:NGD) is $3.86 while their mean recommendation is 3.10 (1=Buy, 5=sell).

If we look at stock performance in last active day trading, we see that stock has moved slumped -1.25% to end the day at $3.16. The current share price indicate that stock is -47.68% away from its one year high and is moving 32.22% ahead of its 52-week low.

Leave a Reply

Your email address will not be published. Required fields are marked *